I just came across this article published on May 6 this year. It looks like GTx has abandoned Osta after phase 3 trials. It was too expensive to run trials for sarcopenia and it was inconclusive for cancer cachexia. Hopefully some other lab will pick it up to run trials for sarcopenia.
The enobosarm saga
The enobosarm saga